ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.2100
+0.0500 (+1.58%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous close3.1600
Open3.1658
Bid2.71 x 1000
Ask6.00 x 1000
Day's range3.1400 - 3.2500
52-week range2.5100 - 10.4390
Volume13,729
Avg. volume25,060
Market cap107.307M
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire17 days ago

    ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring

    ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced a strategic corporate restructuring to focus its resources on its lead clinical programs: varlitinib in biliary tract cancer (BTC), ASLAN003 in acute myeloid leukaemia (AML) and ASLAN004 in atopic dermatitis. ASLAN will focus its resources on the late-stage development of varlitinib as a potential novel treatment for first- and second-line BTC. Enrolment in a global pivotal study of varlitinib in second-line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in December 2018 and topline data is expected in the second half of 2019.

  • GlobeNewswire24 days ago

    ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that new pre-clinical data on varlitinib’s activity in triple negative breast cancer (TNBC) cell lines have been published online in Cancers, a peer-reviewed oncology journal. The data suggest that HER-family signalling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients. The article titled “Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells” details the findings of the pre-clinical study in which investigators evaluated the efficacy of varlitinib, a reversible small molecule pan-HER inhibitor, in TNBC.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced positive data from an ongoing multicentre phase 1b/2 clinical trial (ASLAN001-007) of varlitinib plus gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC). Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “The responses we have seen with varlitinib in this clinical trial are impressive, especially when compared to historical data for the current standard of care, gem/cis for biliary tract cancer. Apart from combination chemotherapy, no progress has been made in the development of new treatment options for BTC patients.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update on its global placebo-controlled, double-blind phase 2 clinical study of varlitinib as a first-line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients, comparing varlitinib plus mFOLFOX6 to placebo plus mFOLFOX6. To date, no targeted therapies have been approved to treat gastric cancer with low HER-family expression.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the U.S. Food and Drug Administration (FDA) has concluded its 30-day review of the Investigational New Drug (IND) application for ASLAN003. The company plans to evaluate ASLAN003 in the United States as part of an ongoing Phase 2 clinical trial. ASLAN003 is a potential treatment for acute myeloid leukaemia (AML), for which the FDA has previously granted Orphan Drug Designation.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the completion of patient enrolment in TreeTopp (TREatmEnT OPPortunity), a global pivotal study investigating varlitinib in second-line biliary tract cancer (BTC). It is the largest global, placebo-controlled study in BTC conducted to date. The study recruited 127 patients who have failed first line therapy from 56 sites worldwide including the US, Europe, Australia, Japan, Korea and other Asia Pacific countries.

  • GlobeNewswire2 months ago

    New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new positive data from the ongoing phase 2a study of ASLAN003 for the treatment of acute myeloid leukaemia (AML) at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, US. ASLAN003 is an orally active, potent inhibitor of dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML. As of 16 November 2018, 14 patients with AML ineligible for standard treatment (including relapsed, refractory and treatment naïve) had been enrolled in the multicentre dose optimisation study to evaluate ASLAN003 monotherapy administered as a 28-day cycle.

  • GlobeNewswire3 months ago

    ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium

    SINGAPORE, Nov. 27, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire3 months ago

    Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation in the 30th Annual Piper Jaffray Healthcare Conference. A live audio webcast of the fireside chat will be available via https://event.webcasts.com/starthere.jsp?ei=1220246&tp_key=5121f6637a with an archived replay link available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event. ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets.